MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens
MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 27 to October 1, 2025, in San Francisco, Calif.
MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes
MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, today announced two studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago, IL. The studies, run in partnership with UCLA, highlight MiraDx’s platform as a predictive tool for treatment toxicity and response to modern cancer immunotherapies.
MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer
MiraDx, a molecular diagnostics company advancing personalized medicine through novel germline biomarkers, announced a groundbreaking study published in the journal Clinical Cancer Research, validating previous findings that its PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led by researchers at UCLA’s Department of Radiation Oncology, the study confirms the effectiveness of PROSTOX ultra, the first test capable of predicting long-term radiation side effects based on a patient’s unique genetic profile. The findings reinforce that radiation toxicity is a biologically unique response for each patient, underscoring the potential to personalize and improve cancer treatment using genetics.
